Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation (NASDAQ: RGEN) is a global life sciences company headquartered in Waltham, Massachusetts, focused on bioprocessing technologies and systems that support the manufacturing of biological drugs. This news page aggregates company announcements, earnings updates, product launches and strategic developments directly related to Repligen’s operations in bioprocessing.
According to its public communications, Repligen serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs), with core focus areas in Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. News items often highlight how these focus areas evolve through new products, partnerships and technology integrations.
Investors and industry followers can use this page to review earnings press releases and related Form 8-K announcements, which cover quarterly financial results, guidance updates and commentary on demand trends across Repligen’s franchises and geographies. The company’s releases also discuss the use of non-GAAP financial measures and provide reconciliations to GAAP results.
Repligen’s news flow additionally includes product and technology updates, such as the launch of new chromatography resins in its proteins portfolio and introductions of equipment in areas like mixing and process analytics. Strategic partnerships, including its collaboration with Novasign to integrate machine learning and modeling workflows into Repligen filtration systems, are another recurring theme.
Governance and leadership developments, such as Board chair transitions and senior finance appointments disclosed via press releases and Form 8-K filings, also appear in the news stream. By checking this page regularly, readers can follow how Repligen describes its progress in bioprocessing technology leadership, digitalization initiatives, and its engagement with the biopharmaceutical and CDMO sectors.
Repligen Corporation (NASDAQ:RGEN) reported a remarkable first-quarter revenue of $142.8 million, reflecting an 88% year-over-year increase and 69% organic growth. Key growth drivers included COVID-related demand contributing 25% of total revenue, alongside a 31% increase in its non-COVID base business. The company also revised its 2021 financial outlook, expecting total revenue between $565-$590 million, significantly up from previous guidance. GAAP EPS rose to $0.52 from $0.18 year-on-year. Adjusted EPS reached $0.68, compared to $0.32 in Q1 2020.
Repligen Corporation (NASDAQ:RGEN) will report its Q1 2021 financial results on May 4, 2021, with a press release issued before market opening. A conference call will be held at 8:30 a.m. EDT to discuss the results for the three-month period ending March 31, 2021. Callers can join via toll-free numbers for domestic and international participants, with no passcode required. The event will also be available for replay. As a leading life sciences company, Repligen specializes in innovative bioprocessing technologies aimed at enhancing biopharmaceutical manufacturing efficiency.
Repligen Corporation (NASDAQ:RGEN) will present virtually at the KeyBanc Life Science and MedTech Investor Forum on March 23-24, 2021. CEO Tony Hunt will participate in a fireside chat on March 24 at 9:15 a.m. EDT. The discussion will be available via live webcast on the company's Investor Relations website, with a replay accessible for a limited time post-event. Repligen specializes in innovative bioprocessing technologies, serving biopharmaceutical developers and contract manufacturers globally, with headquarters in Waltham, Massachusetts.
Repligen Corporation (NASDAQ:RGEN) will present at the Barclays Global Healthcare Conference from March 9-11, 2021. CFO Jon Snodgres is scheduled for a fireside chat on March 10 at 1:50 p.m. EST. A live webcast of this discussion will be available on the Company’s Investor Relations website and will be accessible for replay afterwards. Repligen specializes in innovative bioprocessing technologies for the biopharmaceutical industry, enhancing drug manufacturing efficiency globally.
Repligen Corporation (NASDAQ:RGEN) reported strong fourth quarter 2020 results with revenues of $108.6 million, a 56% year-over-year increase, driven by sales to COVID vaccine accounts. Total annual revenue reached $366.3 million, up 36% year-over-year. Operating income was $17.4 million, a significant rise, with a GAAP EPS of $0.36. For 2021, Repligen projects revenue between $500-$525 million, reflecting a 37%-43% growth rate.
Repligen Corporation (NASDAQ:RGEN) will present virtually at the 10th Annual SVB Leerink Healthcare Conference from February 22-26, 2021. Tony J. Hunt, the President and CEO, is scheduled to participate in a fireside chat on February 26 at 12:00 p.m. EST. Investors can access a live webcast and replay through the Company’s Investor Relations website. Repligen specializes in bioprocessing technologies that enhance the manufacturing of biological drugs, catering mainly to biopharmaceutical developers globally.
Repligen Corporation (NASDAQ:RGEN) has announced a webcast and conference call to discuss its fourth quarter and full year 2020 financial results, scheduled for February 24, 2021 at 8:30 a.m. EST. The financial report will be released before the market opens. Interested parties can join the call by dialing 844-274-3999 for domestic callers or 412-317-5607 for international callers. Repligen develops innovative bioprocessing technologies for biopharmaceutical manufacturers globally and has facilities in various countries including the U.S., Estonia, Germany, and Sweden.
Repligen Corporation (NASDAQ:RGEN) and Navigo Proteins GmbH have announced the commercial launch of the NGL COVID-19 Spike Protein Affinity Resin, designed to enhance the purification process of COVID-19 vaccines. This resin aims to provide a high-purity capture step, reducing processing time and improving yield. The resin meets high-performance standards, including selectivity and dynamic binding capacities. Positive customer feedback has been recorded, with orders for validated resins currently being accepted.
Repligen Corporation (NASDAQ:RGEN) announced its participation in the 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021. CEO Tony J. Hunt will present on January 13 at 9:10 a.m. EST. A live webcast of the presentation will be available on the Company’s investor relations website and will be accessible for replay afterward.
The company, based in Waltham, Massachusetts, focuses on bioprocessing technologies aimed at improving the efficiency of manufacturing biological drugs, serving biopharmaceutical developers and CDMOs globally.
Repligen Corporation (NASDAQ: RGEN) successfully closed its underwritten public offering of 1.725 million shares at $181 each, generating gross proceeds of approximately $312.2 million. After deducting fees, the net proceeds are expected to be about $298 million, intended for working capital and general corporate purposes, including potential investments in complementary businesses. The offering included full exercise of the underwriters’ option for an additional 225,000 shares. The company has no current agreements for acquisitions.